Org 28611

Org 28611

Legal status
Legal status	CA: Schedule II
Identifiers
IUPAC name [1-(cyclohexylmethyl)-7-methoxyindol-3-yl]-[(3S)-3,4-dimethylpiperazin-1-yl]methanone
CAS Number	639068-99-8 N
PubChem CID	10091392
ChemSpider	8266929 Y
ChEMBL	CHEMBL1209709 Y
Chemical and physical data
Formula	C23H33N3O2
Molar mass	383.526 g/mol
3D model (JSmol)	Interactive image
SMILES COc3cccc(c13)c(C(=O)N(CC2C)CCN2C)cn1CC4CCCCC4
InChI InChI=1S/C23H33N3O2/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3/t17-/m0/s1 Y Key:ONXJNAIZJKLJGA-KRWDZBQOSA-N Y
NY (what is this?)  (verify)

Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB₁ and CB₂ receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic,^[1] and while it achieved this aim and has progressed as far as Phase II clinical trials in humans as both a sedative and an analgesic, results against the comparison drugs (midazolam and morphine respectively) were not particularly favourable in initial testing.^[2][3]

See also

• LBP-1
• N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide
• Org 28312

References

1. ↑ Adam, J. M.; et al. (2010). "Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists". MedChemComm. Royal Society of Chemistry. 1: 54. doi:10.1039/c0md00022a. 
2. ↑ Zuurman L, Passier PC, de Kam M, Kleijn HJ, Cohen AF, van Gerven JM (August 2009). "Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers". Journal of Psychopharmacology (Oxford, England). 23 (6): 633–44. PMID 18635703. doi:10.1177/0269881108091551. 
3. ↑ A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery